WEKO3
アイテム
Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study
https://repo.qst.go.jp/records/85152
https://repo.qst.go.jp/records/851525381da7c-9331-4ae2-a880-2f7067bc2dd9
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2022-03-09 | |||||
| タイトル | ||||||
| タイトル | Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Okonogi, Noriyuki
× Okonogi, Noriyuki× Usui, Hirokazu× Murata, Kazutoshi× Hori, Makoto× Kurokawa, Tomoya× Fujiwara, Tadami× Fujii, Yasuhisa× Hanawa, Michiko× Kawasaki, Yohei× Hattori, Yoko× Suzuki, Kazuko× Tsuyuki, Kyoko× Wakatsuki, Masaru× Hasegawa, Sumitaka× Yamada, Shigeru× Hanaoka, Hideki× Shozu, Makio× Tsuji, Hiroshi× Noriyuki, Okonogi× Kazutoshi, Murata× Kazuko, Suzuki× Kyoko, Tsuyuki× Masaru, Wakatsuki× Sumitaka, Hasegawa× Shigeru, Yamada× Hideki, Hanaoka× Hiroshi, Tsuji |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Concurrent chemoradiotherapy is considered the standard treatment strategy for locally advanced cervical cancer. Most recent reports indicate that patients with bulky tumours or adenocarcinoma subtypes have poorer local control. Carbon-ion radiotherapy (CIRT) with the concurrent use of chemotherapy has shown promising results in such cases of difficult-to-treat uterine cervical cancer. Programmed death-ligand 1 (PD-L1) upregulation was observed in tumour tissue samples from patients who had undergone CIRT. Thus, a combination of CIRT and anti-PD-L1 antibody may suppress metastasis by activating antitumour immune response, in addition to exhibiting strong local effects. | |||||
| 書誌情報 |
BMJ open 巻 12, 号 3, p. e056424, 発行日 2022-03 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 2044-6055 | |||||
| PubMed番号 | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 35236732 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1136/bmjopen-2021-056424 | |||||
| 関連サイト | ||||||
| 識別子タイプ | URI | |||||
| 関連識別子 | https://bmjopen.bmj.com/content/12/3/e056424 | |||||
